Table 1:

Previous preclinical studies show that high doses of ERT can treat neurological complications.

Mouse model	Dose (mg/kg)	Clinical dose (mg/kg)	Brain enzyme activity (% Normal)	Brain storage reduced (%Affected)	References
α-mannosidosis	36.6	1	15%	50%	[27]
Metachromatic leukodystrophy	20	N/A	N/A	30%	[26]
Aspartylglycosaminuria	10	N/A	10%	20%	[28]
Krabbe disease	6	N/A	7%	18%	[25]
MPS II	10	0.5	5%	N/A	[22]
MPS IIIA	20	N/A	22%	0	[23]
MPS VII	20	2	2.50%	N/A	[24]
MPS I	20	0.58	97%	63%	[21]